Retatrutide vs Oxytocin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Oxytocin
Oxytocin is a natural hormone produced in the hypothalamus, often called the 'love hormone' or 'bonding hormone.' It plays key roles in social bonding, childbirth, lactation, and stress regulation.
Full details →Side-by-Side Comparison
| Aspect | Retatrutide | Oxytocin |
|---|---|---|
| Mechanism | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. | Binds to oxytocin receptors in the brain and peripheral tissues. Promotes social bonding, reduces anxiety and stress response, and has various peripheral effects on smooth muscle contraction. |
| Typical Dosage | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. | Intranasal: 20-40 IU (international units) for social/anxiolytic effects. Clinical uses (labor induction) require IV administration under medical supervision. |
| Administration | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. | Intranasal spray for behavioral effects. IV only in clinical settings. Sublingual also possible. Best used situationally rather than continuously. |
| Side Effects | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. | Intranasal: headache, nasal irritation, drowsiness. May cause over-attachment or emotional sensitivity. IV (clinical): uterine hyperstimulation, water retention. |
| Best For |